Recommendation ID NG131/3 Question What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate
Recommendation ID NG134/2 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of supported
Recommendation ID NG135/6 Question What methods and techniques help secondary schools and providers to effectively engage with parents
Recommendation ID DG35/1 Question The committee recommended further research to determine if using the lead‑I electrocardiogram (ECG) devices
Recommendation ID DG36/1 Question Further primary research is recommended on the clinical effectiveness of using ELISA tests for therapeutic
Recommendation ID NG135/5 Question How effective are education-based alcohol prevention interventions (universal or targeted) for children
Recommendation ID NG131/4 Question What is the most clinically and cost-effective pathway for excluding the clinically significant progression
Recommendation ID NG25/7 Question At what gestation should treatment with prophylactic vaginal progesterone for the prevention of preterm
Recommendation ID NG25/6 Question Does progesterone reduce the risk of preterm birth in women who have a short cervix (cervical length
Recommendation ID NG25/5 Question Does progesterone reduce the risk of preterm birth in women who have risk factors for preterm birth,
Recommendation ID NG134/1 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological
Recommendation ID CG30/2 Question Most women will need to use contraception for more than 30 years. Patterns of contraceptive use vary
Recommendation ID TA171/1 Question The Committee considered that rigorous data collection is needed on the life-extending benefits of lenalidomide
Recommendation ID NG132/3 Question What are the long-term outcomes of different management strategies for primary hyperparathyroidism?
Recommendation ID NG130/6 Question What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab
Recommendation ID NG130/4 Question What is the clinical and cost effectiveness of prednisolone compared with aminosalicylates for the induction
Recommendation ID NG130/5 Question What is the clinical and cost effectiveness of prednisolone plus an aminosalicylate compared with beclometasone
Recommendation ID NG135/4 Question How effective and cost effective are education-based alcohol interventions targeted at children and
Recommendation ID NG135/2 Question How effective and cost effective are individual, compared with group, education-based interventions
Recommendation ID DG36/2 Question secondary research is recommended to understand the clinical validity of enzyme-linked immunosorbent
Recommendation ID DG36/3 Question Secondary research is recommended to understand the comparative performance of different ELISA tests
Recommendation ID NG130/1 Question In a mild-to-moderate first presentation or inflammatory exacerbation of proctitis that is resistant
Recommendation ID NG130/2 Question What is the effectiveness of oral tacrolimus and systemic (intramuscular/subcutaneous/oral) methotrexate
Recommendation ID NG130/3 Question What is the clinical and cost effectiveness of prednisolone, budesonide, and beclometasone in addition
Recommendation ID NG129/1 Question What are the benefits, risk and cost effectiveness of enteral nutrition in maintaining remission in
Recommendation ID CG30/4 Question The effect of injectable contraceptives on bone mineral density in women who have used DMPA for longer
Recommendation ID NG132/1 Question What is the clinical utility of bone turnover markers in the diagnosis and management of primary...
Recommendation ID NG134/4 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief
Recommendation ID NG134/5 Question What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural
Recommendation ID NG135/1 Question What components of alcohol education delivery contribute to its effectiveness for children and young
Recommendation ID DG35/2 Question The committee recommended that data should be collected to evaluate the system impact of adopting the
Recommendation ID NG131/8 Question What is the effectiveness and cost effectiveness of different scheduling of zoledronic acid in the prevention
Recommendation ID CG30/1 Question Few women use contraception perfectly (that is, exactly in accordance with the product instructions)
Recommendation ID NG135/3 Question How effective and cost effective are universal, education-based alcohol interventions for children and
Recommendation ID CG30/3 Question In addition to individual circumstances and needs, a woman's choice and acceptance of LARC may be influenced
Recommendation ID NG132/2 Question What is the best and most cost-effective management strategy for people whose first surgery for primary
Recommendation ID NG132/4 Question What are the optimal management strategies for primary hyperparathyroidism during pregnancy?
Recommendation ID NG131/5 Question What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term
Study will measure public’s preference for different health states
An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE for use in the Cancer Drugs Fund (CDF).
Draft guidance published today (3 October 2019) by NICE does not recommend atezolizumab (also called Tecentriq and made by Roche) for treating people with a type of breast cancer called triple A breast cancer that has spread to other parts of the body and who can’t have surgery to remove it.
Regularly monitoring women who are pregnant with twins or triplets, to spot any possible complications, can lead to better outcomes for mothers and their babies, as highlighted in NICE’s impact report.
NICE has said that a new drug for preventing migraine is not a cost effective use of NHS resources, in final draft guidance published today (26 September 2019).
Operations are set to start taking place in the NHS
Deborah Duval, the editor of Kidney Matters magazine, tells us how we can enjoy food even on a restricted renal diet
Consultation on priority areas open to stakeholders until mid October
Higher quality evidence would allow NICE to make recommendations on a range of therapies that could help people with tinnitus.
Heidi Livingstone, senior public involvement adviser within NICE's Public Involvement Programme, reflects on the partnership with CMAC
Recruitment for the 2020 intake is open until 28 October 2019
It is estimated that in the UK there are around 30 to 50 children living with the condition